These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8788829)

  • 41. Liposomal drug delivery system from laboratory to clinic.
    Kshirsagar NA; Pandya SK; Kirodian GB; Sanath S
    J Postgrad Med; 2005; 51 Suppl 1():S5-15. PubMed ID: 16519249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
    Ayestarán A; López RM; Montoro JB; Estíbalez A; Pou L; Julià A; López A; Pascual B
    Antimicrob Agents Chemother; 1996 Mar; 40(3):609-12. PubMed ID: 8851579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comment: expense of amphotericin B product.
    Andersen JM
    Ann Pharmacother; 1996 Nov; 30(11):1342. PubMed ID: 8913426
    [No Abstract]   [Full Text] [Related]  

  • 44. Comment: compatibility of amphotericin B with lipid emulsions.
    Montoro JB; López RM; Pou L
    Ann Pharmacother; 1996 Dec; 30(12):1501. PubMed ID: 8968472
    [No Abstract]   [Full Text] [Related]  

  • 45. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures.
    Shadkhan Y; Segal E; Bor A; Gov Y; Rubin M; Lichtenberg D
    J Antimicrob Chemother; 1997 May; 39(5):655-8. PubMed ID: 9184368
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Administration of amphotericin B in lipid emulsion.
    O'Neil MG; Lapointe M
    Crit Care Med; 1997 May; 25(5):892-3; author reply 893-4. PubMed ID: 9187614
    [No Abstract]   [Full Text] [Related]  

  • 47. The use of lipid emulsions for the i.v. administration of a new water soluble polyene antibiotic, SPK-843.
    Mozzi G; Benelli P; Bruzzese T; Galmozzi MR; Bonabello A
    J Antimicrob Chemother; 2002 Feb; 49(2):321-5. PubMed ID: 11815574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amphotericin B and cardiac toxicity--a case report.
    el-Dawlatly AA; Gomaa S; Takrouri MS; Seraj MA
    Middle East J Anaesthesiol; 1999 Feb; 15(1):107-12. PubMed ID: 10068976
    [No Abstract]   [Full Text] [Related]  

  • 49. Comments concerning 'The penetration of amphotericin B from an Intralipid formulation into fibrin loci in a rabbit model of candidiasis'.
    Washington C; Davis SS
    Biopharm Drug Dispos; 1995 Aug; 16(6):529-31. PubMed ID: 7579034
    [No Abstract]   [Full Text] [Related]  

  • 50. Administration of amphotericin B in lipid emulsion.
    Devlin J; Bailey E; Zarowitz B
    Crit Care Med; 1997 May; 25(5):892; author reply 893-4. PubMed ID: 9187613
    [No Abstract]   [Full Text] [Related]  

  • 51. Safety and efficacy of Intralipid emulsions of amphotericin B.
    Herbrecht R; Letscher V
    J Antimicrob Chemother; 1997 Jul; 40(1):137-9. PubMed ID: 9249219
    [No Abstract]   [Full Text] [Related]  

  • 52. Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate---fat emulsion in HIV-infected patients with oral candidosis.
    Chavanet P; Clement C; Duong M; Buisson M; D'Athis P; Dumas M; Bonnin A; Portier H
    Clin Microbiol Infect; 1997 Aug; 3(4):455-461. PubMed ID: 11864156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nutritional impact of lipid-associated amphotericin B formulations.
    Sacks GS; Cleary JD
    Ann Pharmacother; 1997 Jan; 31(1):121-2. PubMed ID: 8997484
    [No Abstract]   [Full Text] [Related]  

  • 54. Stability of amphotericin B 0.05 and 0.5 mg/mL in 20% fat emulsion.
    Owens D; Fleming RA; Restino MS; Cruz JM; Hurd DD
    Am J Health Syst Pharm; 1997 Mar; 54(6):683-6. PubMed ID: 9075499
    [No Abstract]   [Full Text] [Related]  

  • 55. [Lipid vehicles for the parenteral administration of drugs (1): emulsions].
    Bermejo Vicedo T; Hidalgo Correas FJ; Carrasco JM
    Nutr Hosp; 1996; 11(1):7-16. PubMed ID: 8704021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.
    Caillot D; Chavanet P; Casasnovas O; Solary E; Zanetta G; Buisson M; Wagner O; Cuisenier B; Bonnin A; Camerlynck P
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):722-5. PubMed ID: 1425731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies.
    Caillot D; Reny G; Solary E; Casasnovas O; Chavanet P; Bonnotte B; Perello L; Dumas M; Entezam F; Guy H
    J Antimicrob Chemother; 1994 Mar; 33(3):603-13. PubMed ID: 8040124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Amphotericin B intralipid formulation: stability and particle size.
    Ranchère JY; Latour JF; Fuhrmann C; Lagallarde C; Loreuil F
    J Antimicrob Chemother; 1996 Jun; 37(6):1165-9. PubMed ID: 8836819
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The composition of oil phase modulates venous irritation of lipid emulsion-loaded diallyl trisulfide.
    Mao C; Wan J; Chen H; Xu H; Yang X
    Drug Dev Ind Pharm; 2010 Jun; 36(6):698-704. PubMed ID: 20050725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Toxicity of amphotericin B emulsion formulations.
    Washington C; Lance M; Davis SS
    J Antimicrob Chemother; 1993 May; 31(5):806-8. PubMed ID: 8380021
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.